Bone Biologics Corporation (BBLGW)
| Previous Close | 27.21 |
| Open | 28.49 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 32.24 - 32.24 |
| 52 Week Range | 0.70 - 70.44 |
| Volume | |
| Avg. Volume | 92 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks Small Cap Research
BBLG in Good Shape as Testing Continues
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 3Q 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing nicely, the financial picture is also vital. This quarter’s release shows that the company has made further advances in
- Business Wire
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
BURLINGTON, Mass., October 21, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four.
